Skip NavigationSkip to Content
Return Return to Search Results

Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis

  1. Author:
    Brooks, A. D.
    Sayers, T. J.

  2. Author Address

    NCI, SAIC Frederick, Frederick, MD 21702 USA Sayers, TJ, NCI, SAIC Frederick, Bldg 560,Rm 31-67, Frederick, MD 21702 USA
    1. Year: 2005
    2. Date: MAY
  2. Journal: Cancer Immunology Immunotherapy
    1. 54
    2. 5
    3. Pages: 499-505
  4. Type of Article: Article
  1. Abstract:

    Human renal carcinoma cells (RCCs) were sensitized to the apoptotic effects of tumor necrosis factor (TNF) - related apoptosis- inducing ligand ( TRAIL), by treatment with cycloheximide (CHX). In contrast to a previous study, a rapid and dramatic decrease in levels of cellular FLICE ( Fas-associated death domain - like IL-1beta-converting enzyme) inhibitory protein (cFLIP) following cycloheximide treatment was observed in all RCCs studied. The unambiguous detection of this decrease in cFLIP was dependent on the quality of the particular antibody preparation used to detect cFLIP. Cycloheximide treatment caused no major change in levels of pro-caspase-8 or cell surface expression of TRAIL receptors. Therefore, cycloheximide treatment resulted in an increase in the pro-caspase-8 to cFLIP ratio, which correlated with sensitization to TRAIL-mediated apoptosis. Furthermore, treatment of human RCCs with small interfering oligoribonucleotides ( siRNA) for cFLIP caused a reduction of cFLIP protein and sensitized cells to TRAIL-mediated apoptosis. We concluded that in the presence of an intact TRAIL signaling pathway, a significant reduction of cFLIP alone is sufficient to sensitize human RCCs to TRAIL apoptosis

    See More

  1. Keywords:

External Sources

  1. View record in Web of Science®
  2. WOS: 000227449600010

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel